We report a new tumor-directed immunoRNase, a chimeric protein made up of an antibody fragment (single-chain Fv fragment) directed to ErbB2, a cell surface receptor. and a non-toxic, human ribonuclease, which upon cell internalization becomes cytotoxic. The immunoRNase is active as a ribonuclease, specifically binds and selectively kills ErbB2-positive cells. ErbB2 is one of the most specific tumor-associated antigens identified so far. overexpressed on tumor cells of different origin. Its choice as target antigen and that of a non-toxic, human RNase as the killer moiety makes this immunoRNase a new. potentially attractive anticancer agent. (C) 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells / DE LORENZO, Claudia; Nigro, A.; Piccoli, Renata; D'Alessio, Giuseppe. - In: FEBS LETTERS. - ISSN 0014-5793. - STAMPA. - 515:(2002), pp. 208-212. [10.1016/S0014-5793(02)02527-9]
A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.
DE LORENZO, CLAUDIA;PICCOLI, RENATA;D'ALESSIO, GIUSEPPE
2002
Abstract
We report a new tumor-directed immunoRNase, a chimeric protein made up of an antibody fragment (single-chain Fv fragment) directed to ErbB2, a cell surface receptor. and a non-toxic, human ribonuclease, which upon cell internalization becomes cytotoxic. The immunoRNase is active as a ribonuclease, specifically binds and selectively kills ErbB2-positive cells. ErbB2 is one of the most specific tumor-associated antigens identified so far. overexpressed on tumor cells of different origin. Its choice as target antigen and that of a non-toxic, human RNase as the killer moiety makes this immunoRNase a new. potentially attractive anticancer agent. (C) 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
